-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Myrd9xarYws6zIMkHghTfCbh9TjLWTzOkjmUl8CFgtF+zliaUHv/QdWT7QEEgomq
 bjt7cO5unZyOgLtW0K1atA==

<SEC-DOCUMENT>0000950123-06-008915.txt : 20060713
<SEC-HEADER>0000950123-06-008915.hdr.sgml : 20060713
<ACCEPTANCE-DATETIME>20060713105815
ACCESSION NUMBER:		0000950123-06-008915
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060713
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060713
DATE AS OF CHANGE:		20060713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	GRAIN MILL PRODUCTS [2040]
		IRS NUMBER:				131840497
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-64641
		FILM NUMBER:		06959776

	BUSINESS ADDRESS:	
		STREET 1:		65 CHALLENGER ROAD
		CITY:			RIDGEFIELD PARK
		STATE:			NJ
		ZIP:			07660
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		65 CHALLENGER ROAD
		CITY:			RIDGEFIELD PARK
		STATE:			NJ
		ZIP:			07660

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y23027e8vk.txt
<DESCRIPTION>FORM 8-K
<TEXT>
<PAGE>

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 Current Report


     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


         Date of report (date of earliest event reported): July 13, 2006


                        Phibro Animal Health Corporation
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


          New York                  333-64641                    13-1840497
- ----------------------------       ------------              -------------------
(State or other jurisdiction       (Commission                 (IRS Employer
      of incorporation)            File Number)              Identification No.)

                               65 CHALLENGER ROAD
                        RIDGEFIELD PARK, NEW JERSEY 07660
               ---------------------------------------------------
               (Address of principal executive offices) (Zip Code)

                                 (201) 329-7300
               ---------------------------------------------------
               Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|    Written communications pursuant to Rule 425 under the Securities Act (17
       CFR 230.425)

|_|    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
       CFR 240.14a-12)

|_|    Pre-commencement communications pursuant to Rule 14d-2(b) under the
       Exchange Act (17 CFR 240.14d-2(b))

|_|    Pre-commencement communications pursuant to Rule 13e-4(c) under the
       Exchange Act (17 CFR 240.13e-4(c))

================================================================================

<PAGE>

Item 8.01

         Phibro Animal Health Corporation issued a press release concerning its
proposed private offering of $240 million in aggregate principal amount of
senior notes due 2013.

         A copy of the press release is attached as Exhibit 99.1 and
incorporated by reference into this report.

Item 9.01 Financial Statements and Exhibits.


(d)  Exhibits

Exhibit No.                Description
- -----------                -----------

99.1                       Press Release issued July 13, 2006
<PAGE>

                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                PHIBRO ANIMAL HEALTH CORPORATION


Dated: July 13, 2006            By: /s/  Richard G. Johnson
                                    --------------------------------------------
                                    Richard G. Johnson
                                    Chief Financial Officer
                                    (principal financial and accounting officer)
<PAGE>

                                  EXHIBIT INDEX


Exhibit No.                Description
- -----------                -----------

99.1                       Press release issued July 13, 2006
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y23027exv99w1.txt
<DESCRIPTION>EX-99.1: PRESS RELEASE
<TEXT>
<PAGE>

- --------------------------------------------------------------------------------

                                                              Exhibit 99.1
For release: IMMEDIATELY

     For additional information contact: Richard G. Johnson, Chief Financial
Officer, or Richard C. Rosenzweig, General Counsel - (201) 329-7300

             PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES THE PROPOSED
                      OFFERING OF ITS SENIOR NOTES DUE 2013

     Ridgefield Park, New Jersey, July 13, 2006 - Phibro Animal Health
Corporation ("PAHC") announced today the proposed private offering of $240
million in aggregate principal amount of its senior notes due 2013. It is
anticipated that the consummation of the offering will occur on or about July
31, 2006 and the net proceeds from the offering, together with available cash,
will be used to refinance all of the outstanding 13% Senior Secured Notes due
2007 of PAHC and one of its subsidiaries, all of the outstanding 9-7/8% Senior
Subordinated Notes due 2008 of PAHC and all of the outstanding 15% Senior
Secured Notes due 2010 of PAHC Holdings Corporation (its parent), to repay debt
outstanding under the existing domestic senior credit facility of PAHC and to
pay related fees and expenses.

     The new notes will be senior unsecured obligations of PAHC, will bear
interest semi-annually and will be guaranteed by PAHC's existing domestic
subsidiaries and certain of its future domestic subsidiaries.

     The new notes will be issued in a private placement and are expected to be
resold by the initial purchasers to qualified institutional buyers pursuant to
Rule 144A and non-U.S. persons pursuant to Regulation S of the Securities Act of
1933, as amended. The offering of new notes has not been and will not be
registered under the Securities Act of 1933, as amended, and the new notes may
not be offered or sold in the United States absent registration under the
Securities Act of 1933, as amended, or an applicable exemption from the
registration requirements.

     This press release is neither an offer to sell nor a solicitation of an
offer to buy securities.

Company Description

     PAHC is a leading diversified global manufacturer and marketer of a broad
range of animal health and nutrition products, specifically medicated feed
additives ("MFAs") and nutritional feed additives, which it sells throughout the
world predominantly to the poultry, swine and cattle markets. MFAs are used
preventively and therapeutically in animal feed to produce healthy animals. PAHC
is also a specialty chemicals manufacturer and marketer.

Forward-Looking Statements

     This news release contains statements that, to the extent that they are not
recitations of historical fact, constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995, Section 21E
of the Securities Exchange Act of 1934. Such forward-looking information
involves risks and uncertainties that could cause actual results


<PAGE>


to differ materially from those expressed in any such forward-looking
statements. These risks and uncertainties include, but are not limited to, the
following: our substantial leverage and potential inability to service our debt;
our dependence on distributions from our subsidiaries; an expansion of the
regulatory restrictions on the use of medicated feed additives in food producing
animals could result in a decrease in our sales; our dependence on suppliers
having current regulatory approvals and the challenges of replacing any such
suppliers; competition in each of our markets; a material portion of our sales
and gross profits are generated by medicated feed additives; risks associated
with our international operations and significant foreign assets; our dependence
on our Brazilian and Israeli operations; our operations, properties and
subsidiaries are subject to a wide variety of complex and stringent federal,
state, local and foreign environmental laws and regulations; extensive
regulation by numerous government authorities in the United States and other
countries; a substantial amount of outstanding shares of our voting capital
stock is owned by a single stockholder; our raw materials are subject to price
fluctuations; our reliance on the continued operation of our manufacturing
facilities and intellectual property; outbreaks of animal diseases could
significantly reduce demand for our products; the risks of legal proceedings and
general litigation expenses; potential operating hazards and uninsured risks;
the risk of work stoppages; and our dependence on key personnel.


                                       2


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
